CD177, a specific marker of neutrophil activation, is associated with COVID-19 severity and death.
2021
The identification of COVID-19 patients with high-risk of severe disease is a challenge in routine care. We performed cell phenotypic, serum and RNA-seq gene expression analyses in severe hospitalized patients (n = 61). Relative to healthy donors, results showed abnormalities of 27 cell populations and an elevation of 42 cytokines, neutrophil chemo-attractants, and inflammatory components in patients. Supervised and unsupervised analyses revealed a high abundance of CD177, a specific neutrophil activation marker, contributing to the clustering of severe patients. Gene abundance correlated with high serum levels of CD177 in severe patients. Higher levels were confirmed in a second cohort and in ICU than non-ICU patients (P< 0.001). Longitudinal measurements discriminated between patients with the worst prognosis, leading to death, and those who recovered (P = 0.01). These results highlight neutrophil activation as a hallmark of severe disease and CD177 assessment as a reliable prognostic marker for routine care.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
73
References
3
Citations
NaN
KQI